Výsledky vyhledávání - "Eyad Al-Hattab"

Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia

Autor: John McGlothlin, Jithma P. Abeykoon, Eyad Al-Hattab, Aneel A. Ashrani, Michelle A Elliott, Ronald Go, C. Christopher Hook, Animesh Pardanani, Rajiv K. Pruthi, Meera Sridharan, Alexandra P. Wolanskyj

Publikováno v: Blood. 140:5328-5330

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7fe79c7f750654176c0ffd75456a3c8a
https://doi.org/10.1182/blood-2022-159270

Zobrazit plný text záznamu

Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor–positive metastatic breast cancer

Autor: Soley Bayraktar, Sameer Batoo, Sandeep Basu, Stefan Glück, Scott H. Okuno, Eyad Al-Hattab

Publikováno v: Future Oncology. 16:2661-2672

There are three US FDA–approved CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib for patients with HR-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC). They are all equally effective, so the question becomes how to choos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccb12b5f87c9ce02ebf40418e44cc10b
https://doi.org/10.2217/fon-2020-0234

Zobrazit plný text záznamu

Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer

Autor: Sameer Batoo, Scott H. Okuno, Eyad Al-Hattab, Soley Bayraktar, Sandeep Basu, Stefan Glück

Publikováno v: Journal of Carcinogenesis
Journal of Carcinogenesis, Vol 18, Iss 1, Pp 5-5 (2019)

With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d598a603b472fba4785a2506f2d0424c
https://pubmed.ncbi.nlm.nih.gov/31949426

Zobrazit plný text záznamu

Short- and Long-Term Risk Stratification in Acute Coronary Syndromes

Autor: Stefan James, Eyad Al-Hattab, Eric Boersma, Yuling Fu, Lars Wallentin, Michael S. Lauer, Robert M. Califf, Cynthia M. Westerhout, Maarten L. Simoons, Paul W. Armstrong

Publikováno v: Journal of the American College of Cardiology. 48:939-947

OBJECTIVES The purpose of this study was to develop 30-day and 1-year risk stratification models for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients that incorporate quantitative ST-segment depression and novel biomarkers. BACKGR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a13c7e80e53f5b3079940fcef7d5164c
https://doi.org/10.1016/j.jacc.2006.04.085

Zobrazit plný text záznamu

Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers

Autor: Cynthia M, Westerhout, Yuling, Fu, Michael S, Lauer, Stefan, James, Paul W, Armstrong, Eyad, Al-Hattab, Robert M, Califf, Maarten L, Simoons, Lars, Wallentin, Eric, Boersma

Publikováno v: Journal of the American College of Cardiology. 48(5)

The purpose of this study was to develop 30-day and 1-year risk stratification models for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients that incorporate quantitative ST-segment depression and novel biomarkers.Several novel biom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b336fd2f028475fd307318f257482c48
https://pubmed.ncbi.nlm.nih.gov/16949483

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání